Abstract
Drug efflux proteins are widespread amongst microorganisms, including pathogens. They can contribute to both natural insensitivity to antibiotics and to emerging antibiotic resistance and so are potential targets for the development of new antibacterial drugs. The design of such drugs would be greatly facilitated by knowledge of the structures of these transport proteins, which are poorly understood, because of the difficulties of obtaining crystals of quality. We describe a structural genomics approach for the amplified expression, purification and characterisation of prokaryotic drug efflux proteins of the Major Facilitator Superfamily (MFS) of transport proteins from Helicobacter pylori, Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Bacillus subtilis, Brucella melitensis, Campylobacter jejuni, Neisseria meningitides and Streptomyces coelicolor. The H. pylori putative drug resistance protein, HP1092, and the S. aureus QacA proteins are used as detailed examples. This strategy is an important step towards reproducible production of transport proteins for the screening of drug binding and for optimisation of crystallisation conditions to enable subsequent structure determination.
Keywords: Membrane transport, transport protein, drug resistance, antibiotic resistance, multidrug resistance, gene expression, protein production, membrane protein
Current Drug Targets
Title: Microbial Drug Efflux Proteins of the Major Facilitator Superfamily
Volume: 7 Issue: 7
Author(s): Martin K. Pos, Peter J.F. Henderson, Roslyn M. Bill, Melissa H. Brown, Nicholas G. Rutherford, John O'Reilly, Ian T. Paulsen, Ronald A. Skurray, Richard B. Herbert, Kate Langton, Karl Walraven, Patrick Butaye, Massoud Saidijam, Scott Morrison, Johan Meuller, Gerda Szakonyi, Kim E. Bettaney, Alison Ward, Sarah L. Palmer, Christopher J. Hoyle, Zhiqiang Xu, Qinghu Ren and Giulia Benedetti
Affiliation:
Keywords: Membrane transport, transport protein, drug resistance, antibiotic resistance, multidrug resistance, gene expression, protein production, membrane protein
Abstract: Drug efflux proteins are widespread amongst microorganisms, including pathogens. They can contribute to both natural insensitivity to antibiotics and to emerging antibiotic resistance and so are potential targets for the development of new antibacterial drugs. The design of such drugs would be greatly facilitated by knowledge of the structures of these transport proteins, which are poorly understood, because of the difficulties of obtaining crystals of quality. We describe a structural genomics approach for the amplified expression, purification and characterisation of prokaryotic drug efflux proteins of the Major Facilitator Superfamily (MFS) of transport proteins from Helicobacter pylori, Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Bacillus subtilis, Brucella melitensis, Campylobacter jejuni, Neisseria meningitides and Streptomyces coelicolor. The H. pylori putative drug resistance protein, HP1092, and the S. aureus QacA proteins are used as detailed examples. This strategy is an important step towards reproducible production of transport proteins for the screening of drug binding and for optimisation of crystallisation conditions to enable subsequent structure determination.
Export Options
About this article
Cite this article as:
Pos K. Martin, Henderson J.F. Peter, Bill M. Roslyn, Brown H. Melissa, Rutherford G. Nicholas, O'Reilly John, Paulsen T. Ian, Skurray A. Ronald, Herbert B. Richard, Kate Langton , Karl Walraven , Patrick Butaye , Saidijam Massoud, Scott Morrison , Meuller Johan, Szakonyi Gerda, Bettaney E. Kim, Ward Alison, Palmer L. Sarah, Hoyle J. Christopher, Xu Zhiqiang, Ren Qinghu and Benedetti Giulia, Microbial Drug Efflux Proteins of the Major Facilitator Superfamily, Current Drug Targets 2006; 7 (7) . https://dx.doi.org/10.2174/138945006777709575
DOI https://dx.doi.org/10.2174/138945006777709575 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Probiotics and Different Efficacy, How it can be Managed?
Current Drug Therapy Resveratrol and Lifespan in Model Organisms
Current Medicinal Chemistry Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Pathogenesis and Treatment Options
Current Vascular Pharmacology Gold(III) Complexes in the Oncological Preclinical Arena: From Aminoderivatives to Peptidomimetics
Current Topics in Medicinal Chemistry DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued) Tumor-Targeting Peptides: Ligands for Molecular Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry Cyclin Dependent Kinase 1 Inhibitors: A Review of Recent Progress
Current Medicinal Chemistry Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis
Current Stem Cell Research & Therapy Use of Natural Gums and Mucilages as Pharmaceutical Excipients
Current Pharmaceutical Design Mechanisms of Herb-Induced Nephrotoxicity
Current Medicinal Chemistry Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Inflammation and Anemia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry <i>Fernandoa Adenophylla</i>: A review of its Phytochemistry, Traditional and Pharmacology use and Future Aspects
Current Traditional Medicine Medication-Induced Acute Abdominal Pain: Evaluation with CT Imaging
Current Medical Imaging Identification of Biomarkers and Functional Modules from Genomic Data in Stage-wise Breast Cancer
Current Bioinformatics Targeting Cancer Stem Cells with Natural Products
Current Drug Targets Past, Present and Future of Nutrigenomics and its Influence on Drug Development
Current Drug Discovery Technologies Role of Lipoxins and Resolvins as Anti-Inflammatory and Proresolving Mediators in Colon Cancer
Current Molecular Medicine Comparative Safety Assessment Study for Drospirenone Induced Gallbladder Diseases Using the Adverse Drug Reaction Database of USA, Europe, and Canada
Current Drug Safety A Dig Deep to Scout the Pharmacological and Clinical Facet of Garlic (<i>Allium sativum</i>)
Current Traditional Medicine